An analysis of TAILORx showed that adding clinical risk refines its genomic risk model and may now identify a group of premenopausal women who may benefit from chemotherapy added to endocrine therapy.
Medscape Medical News
An analysis of TAILORx showed that adding clinical risk refines its genomic risk model and may now identify a group of premenopausal women who may benefit from chemotherapy added to endocrine therapy.
Medscape Medical News
